A new study published in the Journal of American Medical Association (JAMA) showed that tumor-treating field (TTF) devices help to improve overall survival and delayed tumor recurrence for glioblastoma patients.
A research team at the University of Basel in Switzerland has identified that the Notch pathway, a cell-signaling pathway central to brain stem activity and previously associated with the growth of gliomas, could actually suppress the formation of glioma brain tumors.
A new study presented at the Society for Neuro-Oncology conference last week reported that cancer vaccine, rindopepimut, has been shown to reduce the risk of death for glioblastoma (GBM) patients by 47 percent.
The EF-14 trial achieved statistically significant extension of both progression-free survival and overall survival in newly diagnosed glioblastoma with a 50% increase in the number of patients alive two-years after starting treatment when treated with TTFields in combination with temozolomide as compared to temozolomide alone.
A new study reveals that while brain metastases share some genetic characteristics with their primary tumors, they also carry unique genetic mutations. The study also report that brain metastases may continue to evolve after leaving the primary tumor site.